Clinical efficacy evaluation of Qingda Granule in the treatment of hypertension (grade 1, low to medium-risk) patients: a multicenter, randomized, double-blind, double-simulated, parallel-controlled, non-inferiority clinical study

Phase 1

Recruiting

• Conditions: hypertension

• Registration Number: ITMCTR2000003400
• Lead Sponsor: Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-02-20

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the diagnostic criteria for essential hypertension measured in the same clinic, the hypertension is graded as grade 1, and the risk stratification is low to medium risk (refer to the 2018 Revision of Chinese Guidelines for The Prevention and Treatment of Hypertension);
2. Did not take or did not take blood pressure medicine regularly within one month;
3. Between 20 and 75 years old (including boundary value);
4. Agree to sign the informed consent.

Exclusion Criteria

1. Patients with obvious liver and kidney diseases or with ALT and AST 1.5 times higher than ULN, Cr and BUN higher than ULN;
2. Patients with serious mental illness, hematopoietic disease, malignant tumor and other major diseases;
3. Women who are pregnant or preparing for pregnancy, and women who are breastfeeding;
4. Have participated in or are participating in other clinical researchers in the past three months;
5. Suspected or definite allergy to the study drug.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified